ArticleFrontiers in neurology2025
Edaravone Dexborneol in acute ischemic stroke patients treated with combined intravenous thrombolysis and mechanical thrombectomy for large vessel occlusion.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of edaravone dexborneol in acute ischemic stroke patients undergoing endovascular thrombectomy: a systematic review and meta-analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Adjuvant neuroprotective therapies for acute ischemic stroke in the reperfusion era: a comparative narrative review of clinical evidence for edaravone, edaravone-dexborneol, and butylphthalide.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mechanical thrombectomy (MT), when combined with intravenous thrombolysis (IVT), has emerged as an effective therapeutic strategy for acute ischemic stroke (AIS). Edaravone Dexborneol, a novel fixed-dose combination of edaravone (30 mg) and dexborneol (7.5 mg) with dual free radical scavenger, has also demonstrated neuroprotective benefits in AIS management. This study aims to investigate the potential effects of Edaravone Dexborneol in patients with AIS who have undergone MT and IVT. Methods: This single-center retrospective cohort study enrolled 207 patients with AIS who received both IVT and MT between January 2019 and June 2024. Based on whether they received Edaravone Dexborneol treatment, patients were categorized into the Edaravone Dexborneol group and the control group. Baseline characteristics, inflammatory biomarkers, functional outcomes, mortality, and safety endpoints were compared. Results: Compared to the control group, the Edaravone Dexborneol group showed significantly lower levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and higher levels of anti-inflammatory cytokines (IL-10, IL-35, TGF-β) at Days 3, 7, and 14 (all Conclusion: Patients treated with Edaravone Dexborneol were associated with better functional outcomes three months after stroke onset compared to those who did not receive the treatment. These findings may be related to the drug's anti-inflammatory properties; however, randomized controlled trials are needed to confirm efficacy in patients undergoing MT combined with IVT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.